BioCentury
ARTICLE | Company News

Merck KGaA puts CAR T development in Intrexon's hands

December 20, 2018 10:54 PM UTC

Merck KGaA (Xetra:MRK) has become the latest pharma to realize early stage CAR T technologies may be best in the hands of smaller companies after transferring to Intrexon Corp. (NYSE:XON) development rights for partnered CAR T therapies.

Merck will purchase $150 million in Intrexon stock and pay $25 million in cash. The pharma will additionally receive a $25 million convertible note...

BCIQ Company Profiles

Merck KGaA

Precigen Inc.